Barclays assumed coverage on shares of ZimVie (NASDAQ:ZIMV – Get Rating) in a report released on Wednesday morning, The Fly reports. The brokerage issued an underweight rating and a $9.00 target price on the stock.
ZimVie Stock Performance
NASDAQ:ZIMV opened at $8.21 on Wednesday. The stock has a 50-day moving average price of $8.65 and a 200 day moving average price of $13.42. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. ZimVie has a 12-month low of $6.67 and a 12-month high of $50.40.
Get ZimVie alerts:ZimVie (NASDAQ:ZIMV – Get Rating) last announced its earnings results on Wednesday, November 9th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.22. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. The firm had revenue of $214.58 million during the quarter, compared to analysts' expectations of $214.83 million. On average, sell-side analysts expect that ZimVie will post 1.95 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ZimVie
A number of large investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd purchased a new stake in shares of ZimVie in the third quarter valued at approximately $27,000. US Bancorp DE purchased a new position in shares of ZimVie during the third quarter worth $36,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of ZimVie during the third quarter worth $46,000. Strs Ohio acquired a new stake in shares of ZimVie in the third quarter valued at $47,000. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of ZimVie in the third quarter valued at $47,000. Institutional investors and hedge funds own 74.62% of the company's stock.About ZimVie
(Get Rating)
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
Featured Articles
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.